Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration

Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial monthly intravitreal aflibercept for the Japanese age related macular degeneration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age-Related Macular Degeneration Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Surugadai Nihon university hospital

Chiyoda-ku, Tokyo, 101-8309, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of age-related macular degeneration

Exclusion criteria

Any treatment before intravitreal Aflibercept for age-related macular degeneration.
Visual acuity above 0.1 in decimal visual acuity

Treatment and study plan

aflibercept

Drug

Primary outcomes

Visual acuity after treatment by PRN or 2 months intravitreal Aflibercept

Time frame: one year

Sponsors and collaborators

Lead sponsor

Nihon University

Other

Registry information

Official study title

Study of PRN and Every 2months Intravitreal Aflibercept After 3 Initial Monthly Injection for Age Related Macular Degeneration

Important dates

Study start: 2013
Primary completion: 2014
Study completion: 2015
First posted: Apr 4, 2013
Registry last updated: Oct 7, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed